Literature DB >> 31132505

Symptomatic Cavernous Malformation Presenting with Seizure without Hemorrhage: Analysis of Factors Influencing Clinical Presentation.

Edoardo Agosti1, Kelly D Flemming2, Giuseppe Lanzino1.   

Abstract

BACKGROUND: Supratentorial cavernous malformations (CMs) can be epileptogenic lesions. However, little is known about clinical comorbidities, medication use, and radiologic features that predict a first seizure presentation without associated CM hemorrhage.
METHODS: We queried a prospective registry of consecutive patients with CM established in January 2015. Data regarding clinical presentation, comorbid conditions, daily medication use, and radiologic CM characteristics were collected. Univariate and multivariate regression analysis was performed assessing variables for presentation with seizure without hemorrhage with P values, odds ratios, and 95% confidence intervals reported.
RESULTS: Of 202 patients, 58.4% were women, and the average age at diagnosis was 43.7 ± 16.5 years. Of the patients, 59.4% were symptomatic. In 40.6%, the CM was an incidental finding. Of the 30 patients who presented with a first-time seizure without concomitant hemorrhage, the mean age at diagnosis was 38.4 ± 14.6 years, and 56.7% were women. Compared with incidental CM, patients with seizure without hemorrhage were younger, had a cortically based, supratentorial lesion, and were less likely to have chronic inflammatory disease or to use aspirin, vitamin D, or statin. Compared with other supratentorial lesions, patients with seizure without hemorrhage more commonly had a temporal lobe CM.
CONCLUSIONS: These prospective data provide possible clues to radiologic factors, clinical comorbidities, and medication influences on seizure presentation in patients with CM. Further multicenter studies would be helpful to determine if disease-modifying agents in addition to epileptic medications or surgery might be helpful.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cavernoma; Cavernous malformation; Clinical presentation; Seizure

Mesh:

Year:  2019        PMID: 31132505     DOI: 10.1016/j.wneu.2019.05.157

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

1.  Seizure Incidence Rates in Children and Adults With Familial Cerebral Cavernous Malformations.

Authors:  Christine K Fox; Jeffrey Nelson; Charles E McCulloch; Shantel Weinsheimer; Ludmila Pawlikowska; Blaine Hart; Marc Mabray; Atif Zafar; Leslie Morrison; Joseph M Zabramski; Amy Akers; Helen Kim
Journal:  Neurology       Date:  2021-08-13       Impact factor: 11.800

Review 2.  Cerebral cavernous malformation remnants after surgery: a single-center series with long-term bleeding risk analysis.

Authors:  Marco M Fontanella; Edoardo Agosti; Luca Zanin; Lodovico Terzi di Bergamo; Francesco Doglietto
Journal:  Neurosurg Rev       Date:  2020-11-19       Impact factor: 3.042

Review 3.  Statins as antiepileptogenic drugs: Analyzing the evidence and identifying the most promising statin.

Authors:  Yousif Hufthy; Mahima Bharadwaj; Shubhi Gupta; Delwar Hussain; Prince Josiah Sajanthan Joseph; Alizah Khan; Jessica King; Pieter Lahorgue; Ovin Jayawardena; Danial Rostami-Hochaghan; Chloe Smith; Anthony Marson; Nasir Mirza
Journal:  Epilepsia       Date:  2022-06-10       Impact factor: 6.740

4.  Displacement of Gray Matter and Incidence of Seizures in Patients with Cerebral Cavernous Malformations.

Authors:  Chi-Jen Chou; Cheng-Chia Lee; Ching-Jen Chen; Huai-Che Yang; Syu-Jyun Peng
Journal:  Biomedicines       Date:  2021-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.